Therapeutic approaches aimed at these axes, such as fucosylated glycan mimetics to reinstate Fut2-mediated symbiosis or microbiota transplantation to rectify MyD88-associated communities, show potential for IBD and metabolic disorders, highlighting that intestinal immune genetics serve as principal regulators of microbial community. This evidence concerns the gene FUT2 and inflammatory bowel disease.